Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMABusiness Wire • 10/01/21
Omeros Corporation's (OMER) CEO Greg Demopulos on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021Business Wire • 08/03/21
Omeros' Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant PatientsBenzinga • 06/14/21
Omeros' Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology AssociationBusiness Wire • 06/14/21
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine AddictionBusiness Wire • 06/10/21
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with NarsoplimabBusiness Wire • 05/28/21
Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association CongressBusiness Wire • 05/13/21
Omeros Corp (OMER) CEO Gregory Demopulos on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21